New hope for tough brain cancer: trial tests powerful drug cocktail
NCT ID NCT02203526
Summary
This study is testing a new combination of drugs for a rare and aggressive brain cancer called primary central nervous system lymphoma. The main goal is to find the safest and most effective dose of a targeted drug called ibrutinib when given with a specific chemotherapy regimen. The trial is for adults whose cancer has come back or did not respond to prior treatment, or for some who are newly diagnosed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.